{"title":"优化方案是干细胞治疗脑卒中临床应用的关键","authors":"M. H. Shirazi, S. Hosseini","doi":"10.4172/2169-0111.1000145","DOIUrl":null,"url":null,"abstract":"Stroke is the second cause of mortality in industrial countries after ischemic heart disease. Ischemic stroke results from an artery occlusion and leads to oxygen and glucose shortage in brain. Cerebral ischemia results in inflammation and oxidative stress leading to neuronal loss and brain damage. To these days, rt-PA is the only approved drug for stroke; however, increasing the risk of bleeding and golden time limitation are the problems associated with rt-PA.","PeriodicalId":89733,"journal":{"name":"Advancements in genetic engineering","volume":"2016 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2169-0111.1000145","citationCount":"2","resultStr":"{\"title\":\"Optimized Protocol is the Key for Clinical Use of Stem Cell Therapy in Stroke\",\"authors\":\"M. H. Shirazi, S. Hosseini\",\"doi\":\"10.4172/2169-0111.1000145\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Stroke is the second cause of mortality in industrial countries after ischemic heart disease. Ischemic stroke results from an artery occlusion and leads to oxygen and glucose shortage in brain. Cerebral ischemia results in inflammation and oxidative stress leading to neuronal loss and brain damage. To these days, rt-PA is the only approved drug for stroke; however, increasing the risk of bleeding and golden time limitation are the problems associated with rt-PA.\",\"PeriodicalId\":89733,\"journal\":{\"name\":\"Advancements in genetic engineering\",\"volume\":\"2016 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4172/2169-0111.1000145\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advancements in genetic engineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2169-0111.1000145\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advancements in genetic engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2169-0111.1000145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Optimized Protocol is the Key for Clinical Use of Stem Cell Therapy in Stroke
Stroke is the second cause of mortality in industrial countries after ischemic heart disease. Ischemic stroke results from an artery occlusion and leads to oxygen and glucose shortage in brain. Cerebral ischemia results in inflammation and oxidative stress leading to neuronal loss and brain damage. To these days, rt-PA is the only approved drug for stroke; however, increasing the risk of bleeding and golden time limitation are the problems associated with rt-PA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
